Why Is ROIVANT SCIENCES LTD (ROIV) Stock Up Today?

ROIV stock surged 18.75% to $41.48 on Monday, reaching a 52-week high, driven by positive Phase 2 trial results for its experimental drug, mosliciguat, which met endpoints in treating pulmonary hypertension. The drug’s success in the PHocus study sparked strong investor interest, propelling the stock to its highest level since its 52-week low of $12.53. The move also coincided with the company’s presentation at the Wells Fargo Healthcare Conference, which added to the momentum.

What Happened

Roivant Sciences announced that mosliciguat, its investigational therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD), met its primary and secondary endpoints in the Phase 2 PHocus trial. The drug demonstrated significant improvements in functional capacity and pulmonary vascular resistance, which are key indicators of treatment effectiveness. The results were disclosed in a press release and discussed in detail during the company’s presentation at the Wells Fargo 21st Annual Healthcare Conference on September 8. The positive data led to a sharp rise in investor sentiment, with the stock climbing nearly 19% in a single session.

In addition to the trial results, two separate price targets were raised for ROIV. H.C. Wainwright increased its price target to $47 from $41, while Jefferies raised its target to $52. These upgrades signaled growing confidence in the stock’s potential, even as the company remains unprofitable with a trailing twelve-month revenue decline of 67.6% and an EPS of -0.49.

What The Data Shows

The stock has risen 13.2% over the past eight sessions, moving from $36.76 to $41.62. Options activity also showed a strong skew toward calls, with $8.2 million in call premiums compared to just $71,000 in puts. The largest single print in the last 36 hours was $4.4 million, indicating significant institutional or large retail interest. Meanwhile, insider transactions over the past 90 days have totaled $247.5 million in sales, with no insider buys recorded. The stock also printed its 18th 52-week high on September 8, reinforcing its recent strength.

What To Watch

The stock is currently trading near its 52-week high, and no near-term earnings date is listed. Investors will likely monitor coverage breadth and any further developments in the mosliciguat pipeline, as well as the response from the broader market to the recent price target upgrades.